Immunotherapy —— KN330
Our thoughts on tumor
In the face of the world-wide problem of tumor, the main problem we think about is how to wake up the animal’s own immune system to fight tumor, rather than increasing additional immune power into animals. In the tumor microenvironment, the number of some important immune cells is very small, and their activity is also severely inhibited. If we can actively recruit NK cells, DC cells, T cells and other immune cells into tumors and improve the activity of these immune cells, they may play an anti-tumor role. These immune cells are an integral part of the immune system and the immune response. Their effective activation is an important prerequisite for the recovery of immune system to kill tumor cells continuously.
Features
Our data show that KN330 has the ability to actively recruit NK cells, macrophages, DC cells, T cells, etc. into tumors, and has the ability to activate these cells. In the follow-up animal experiments, as we expected, KN330 showed amazing tumor eradication ability and excellent safety.
Possible indications
The ability to actively recruit immune cells gives KN330 wider indication. We don’t have to worry about whether this is a hot tumor or a cold tumor. In either case, KN330 can allow immune cells to infiltrate into the tumor, and the latter will play an anti-tumor role. Therefore, we can speculate that KN330 is applicable to malignant tumors in all parts of body including the liver, lung, breast, skin, nervous system, as well as malignant tumors of all cell sources such as soft tissue cells, squamous cells, glandular cells, hepatocytes, epithelial cells, mast cells, lymphocytes, etc. In hundreds of mouse models of various types and hundreds of real-world dog / cat cases, the indication range of KN330 is consistent with our speculation.
Similar Studies
Until 2021, no drug similar to the design idea of KN330 had been reported. The paper jointly published by BioNTech and Sanofi in 2021 shows that the drugs they designed with similar drug design schemes (BioNTech code BNT131, Sanofi code SAR441000) show surprising efficacy and safety similar to those of KN330.
About us
The team
Knockgene was founded by several highly creative scientists from China. The main office locates in Beijing. The team believes that de novo designed drug can treat diseases better. With our unique insights into the immune system and the innovative drug screening platform, we have made some interesting discoveries in the field of immune related diseases. We look forward to finding more drugs with excellent efficacy and reliable safety.
Our mission
The team is committed to developing the first in class immunotherapeutic drugs. The company is established to the development and improvement of the drugs in the companion animal market.
Investment & Cooperation
If you want to invest, patent licensing, joint development cooperation, welcome!